Data Foundry

Drug recalls 2025

Doxepin Hydrochloride Capsules — Class II drug recall D-0566-2025

Ongoing recall by Alembic Pharmaceuticals Limited, reported 2025-08-13, distributed nationwide. CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Recall numberD-0566-2025
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmAlembic Pharmaceuticals Limited, Panchmahal, N/A, India
Recall initiated2025-07-25
Classified2025-08-01
Reported by FDA2025-08-13
DistributedNationwide (US)
Quantity9,492 bottles
Reason classeschemical contamination, cgmp, specification failure
NDC62332-0637, 62332-0637-31, 62332-0637-91, 62332-0638, 62332-0638-31, 62332-0638-91, 62332-0639, 62332-0639-31, 62332-0639-91, 62332-0640, 62332-0640-31, 62332-0640-91, 62332-0645, 62332-0645-31, 62332-0645-91
Lot numbers2305015142
Expiration dates2025-09-30

Product

Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31

Reason for recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0566-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.